Lexicon Pharmaceuticals, Inc. (LXRX:NASDAQ) closed at $1.60 on October 21, 2026, up 0.95% on the day. The stock trades 40.5% below its 52-week high of $2.68 and 45.0% above its 52-week low of $1.10. Over the past year, it gained 13.7%. Lexicon Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 20, 2025, LXRX closed higher on 114 days (45%). Its best day was January 21, 2026 (+19.08%) and its worst was January 30, 2026 (-19.44%). The stock moved 10% or more in a single session 10 times.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Find more stocks like LXRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.